hypoxanthine chlorohydrate | 66757-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: hypoxanthine chlorohydrate
• 英文别名: Hypoxanthine hydrochloride；1,7-dihydropurin-6-one;hydrochloride
• CAS: 66757-17-3
• 化学式: C₅H₄N₄O*ClH
• 分子量: 172.574
• InChiKey: HHQJQDNNYDGYLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.93
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  hypoxanthine chlorohydrate 、 copper dichloride 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Quiros Olazabal, M.; Salas Peregrin, J. M.; Sanchez Sanchez, M. P., Thermochimica Acta, 1986, vol. 103, p. 305 - 316

  摘要：

  DOI：

文献信息

• Histone deacetylase inhibitors
  申请人：CircaGen Pharmaceutical, a Delaware corporation

  公开号：US20020143037A1

  公开（公告）日：2002-10-03

  Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

  组蛋白去乙酰化酶是一种在活性位点含锌的金属酶。具有锌结合基团的化合物，例如，羧酸基团，可以抑制组蛋白去乙酰化酶。组蛋白去乙酰化酶的抑制可以抑制基因表达，包括与肿瘤抑制相关的基因的表达。因此，抑制组蛋白去乙酰化酶可以提供治疗癌症、血液学疾病（例如血红蛋白病）以及遗传相关代谢性疾病（例如囊性纤维化和肾上腺白质脑病）的另一途径。
• [EN] HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS<br/>[FR] INHIBITEURS D'HISTONE DESACETYLASE BASES SUR DES COMPOSES ALPHA-CETO-EPOXYDES
  申请人：BEACON LAB INC

  公开号：WO2003099272A1

  公开（公告）日：2003-12-04

  Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g., spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.

  组蛋白去乙酰化酶是一种在活性位点含锌的金属酶。具有结合锌的基团的化合物，例如α-酮环氧基团，如α-酮硫基团，可以抑制组蛋白去乙酰化酶。组蛋白去乙酰化酶的抑制可以抑制基因表达，包括与肿瘤抑制相关的基因的表达。因此，抑制组蛋白去乙酰化酶可以提供治疗癌症、血液学疾病（例如血红蛋白病）、常染色体显性疾病（例如脊髓性肌萎缩症和亨廷顿病）、遗传相关代谢性疾病（例如囊性纤维化和肾上腺白质脑病）或在体外刺激造血细胞的替代途径。
• [EN] HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS<br/>[FR] INHIBITEURS D'HISTONE DESACETYLASE A BASE DE COMPOSES DE TRIHALOMETHYLCARBONYLE
  申请人：BEACON LAB INC

  公开号：WO2003099760A1

  公开（公告）日：2003-12-04

  Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, a trihalomethylcarbonyl group, such as a trifluoromethylcarbonyl group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemaglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.

  组蛋白去乙酰化酶是一种在活性位点含锌的金属酶。具有结合锌的基团的化合物，例如三卤甲基羰基基团，如三氟甲基羰基基团，可以抑制组蛋白去乙酰化酶。组蛋白去乙酰化酶的抑制可以抑制基因表达，包括与肿瘤抑制相关的基因的表达。因此，抑制组蛋白去乙酰化酶可以提供治疗癌症、血液学疾病（例如血红蛋白病）、常染色体显性疾病（例如脊髓性肌萎缩症和亨廷顿病）、遗传相关代谢性疾病（例如囊性纤维化和肾上腺白质脑病）或在体外刺激造血细胞的替代途径。
• [EN] HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS<br/>[FR] INHIBITEURS D'HISTONE DESACETYLASE BASES SUR DES COMPOSES ALPHA-CHALCOGENMETHYLCARBONYLE
  申请人：BEACON LAB INC

  公开号：WO2003099789A1

  公开（公告）日：2003-12-04

  Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-chalcogenmethylcarbonyl group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington’s disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.

  组蛋白去乙酰化酶是一种含锌活性位点的金属酶。具有锌结合基团的化合物，例如α-硫代酮基团，可以抑制组蛋白去乙酰化酶。组蛋白去乙酰化酶的抑制可以抑制基因表达，包括与肿瘤抑制相关的基因的表达。因此，抑制组蛋白去乙酰化酶可以提供治疗癌症、血液学疾病（例如血红蛋白病）、常染色体显性疾病（例如脊髓性肌萎缩症和亨廷顿病）、遗传相关代谢性疾病（例如囊性纤维化和肾上腺白质脑病）或刺激体外造血细胞的替代途径。
• Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
  申请人：Lan-Hargest Hsuan-Yin

  公开号：US20050282890A1

  公开（公告）日：2005-12-22

  Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.

  组蛋白去乙酰化酶是一种含锌活性位点的金属酶。具有结合锌的基团的化合物，例如α-酮酰环氧基团，如α-酮硫基团，可以抑制组蛋白去乙酰化酶。组蛋白去乙酰化酶抑制可以抑制基因表达，包括与肿瘤抑制相关的基因表达。因此，抑制组蛋白去乙酰化酶可以提供一种替代途径用于治疗癌症、血液学疾病，例如血红蛋白病、常染色体显性疾病，例如脊髓肌萎缩症和亨廷顿病，遗传相关代谢性疾病，例如囊性纤维化和肾上腺白质病，或刺激外体造血细胞。